Trifluridine/Tipiracil Tablets 150mg-Shouqi
$1.00
Trifluridine/Tipiracil Tablets (brand: Shouqi®) combine a nucleoside analog (trifluridine) and a thymidine phosphorylase inhibitor (tipiracil) in a 1:0.5 molar ratio. Each box contains 20 film-coated tablets (15?mg trifluridine + 7.06?mg tipiracil per tablet). Manufactured by Zhejiang Chia Tai Tianqing Pharma Group Co., Ltd., registered under China NMPA No.?H20213714 and product code 86901523002581.
?? For laboratory research use only.?Please consult the staff for other purposes?
描述
Trifluridine/Tipiracil Tablets Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Trifluridine/Tipiracil Tablets (Shouqi®) |
| Generic Names | Trifluridine & Tipiracil Hydrochloride |
| Strength | 15?mg/7.06?mg per tablet |
| Pack Size | 10 tablets ×?2 blisters = 20 tablets per box |
| CAS Numbers | Trifluridine: 70?00?8; Tipiracil HCl: 183204?72?0 :contentReference[oaicite:5]{index=5} |
| Molecular Formulas & Weights | Trifluridine: C??H??F?N?O? (~296.2?g/mol); Tipiracil·HCl: C?H??ClN?O?·HCl (~279.1?g/mol) :contentReference[oaicite:6]{index=6} |
| Dosage Form | Film-coated oral tablet |
| Approval Number | H20213714 (China NMPA) |
| Product Code | 86901523002581 |
| Manufacturer | Chia Tai Tianqing Pharma Group Co., Ltd. |
| Barcode | 6922096211204 |
| Storage | Store below 30?°C, protect from moisture |
| Intended Use | Laboratory research only |
Trifluridine/Tipiracil Tablets Mechanism of Action
Trifluridine incorporates into DNA, causing dysfunction, while tipiracil inhibits thymidine phosphorylase— preventing trifluridine degradation and enhancing its bioavailability tga.gov.au+15lonsurfhcp.com+15en.wikipedia.org+15.
Research Applications & Pharmacology
-
Oncology research: Preclinical studies in chemorefractory colorectal and gastric cancers en.wikipedia.org+7tandfonline.com+7pubmed.ncbi.nlm.nih.gov+7
-
Mechanistic assays: DNA incorporation studies, combination with bevacizumab
-
In vitro/in vivo dosing: Clinical dosing ~35?mg/m² BID; rodent models adjust accordingly
-
Pharmacokinetics: Trifluridine absorbed ?57%; high protein binding (>96%); tipiracil increases plasma exposure 22–37× by inhibiting degradation
Safety Profile & Side Effects
Common adverse events include myelosuppression (neutropenia, anemia, leukopenia), nausea, fatigue, diarrhea, and hand–foot syndrome.
Lab safety advice: Use PPE, monitor blood counts in animal studies, and manage neutropenia proactively.
?? Research?Use Disclaimer
This product is intended exclusively for laboratory research use. It is not approved for clinical, diagnostic, therapeutic, or veterinary purposes. Misuse may pose safety risks and result in unreliable scientific data.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Lparomlimab & Tuvonralimab Injection (Qibeian) – 50?mg/2?mL Vial Price comparison
Lparomlimab & Tuvonralimab Injection Qibeian is a bi-functional monoclonal antibody combination (PD?1/CTLA?4) developed by Qilu Pharmaceutical (QL1706), supplied as 50?mg in 2?mL vials. Approved by China’s NMPA (conditional marketing authorization No. S20240044; drug code 86904021005238). Intended exclusively for lab and investigative research applications, not for clinical or human use. $1.00 -
Pirtobrutinib Tablets (Jaypirca) – 100?mg × 14 Tablets × 4 Blisters Price comparison
Pirtobrutinib Tablets (brand name: Jaypirca) is the world’s first non-covalent BTK inhibitor, provided here as 100?mg oral film?coated tablets. Manufactured by Lilly del Caribe, Inc. and approved for import in China (NMPA No. HJ20240116; code 86978403001613). Supplied with clear indication for research/investigational use only, not for human therapeutic use. $2.00 -
Granisetron Hydrochloride Dispersible Tablets Price comparison
A 5-HT? receptor antagonist—Granisetron Hydrochloride Dispersible Tablets by Guangxi Mingjian Pharmaceutical Co., Ltd. (Guimingjian). Packaged as 1?mg tablets, 4 tablets per blister × 2 blisters per box. Approved in China (NMPA No. H20020303; product code 86905130000183). Primarily intended for clinical prevention and treatment of nausea/vomiting induced by chemotherapy, radiation, or surgery. For research use only $1.00 -
Ivodazumab Injection (lvonescimab) – 10?ml per Vial [For Laboratory Research Only]
Ivodazumab (Yidafang®) is a monoclonal antibody developed by Kangfang Pharmaceutical Co., Ltd., approved by China's NMPA (Approval No. S20240020; Drug Code: 86985204000011). Each vial contains 10?ml of the injectable formulation. Strictly for laboratory research use only—not for clinical or human use.
$1.00
评价
目前还没有评价